Showing results (71-80 of 89) with videos related to
Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclinesJeffrey H Silber, Avital Cnaan, Bernard J Clark, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2004
Using health-related quality of life measures to predict cardiac function in survivors exposed to anthracyclinesJill P Ginsberg, Avital Cnaan, Huaqing Zhao, et al.Circulation. Heart Failure|June 19, 2025
Impact of Neighborhood Factors on Exercise Capacity in Children With Hypertrophic CardiomyopathyImran R Masood, Lei Wang, Helen M Stanley, et al.Journal of the American College of Cardiology|August 2, 2014
D-transposition of the great arteries: the current era of the arterial switch operationJuan Villafañe, M Regina Lantin-Hermoso, Ami B Bhatt, et al.Pediatric Cardiology|September 25, 2020
Exercise Capacity and Predictors of Performance After Fontan: Results from the Pediatric Heart Network Fontan 3 StudyDavid J Goldberg, Victor Zak, Brian W McCrindle, et al.Pulmonary Circulation|July 4, 2024
Creating a digital approach for promoting physical activity in pediatric pulmonary hypertension: A framework for future interventionsCatherine M Avitabile, Jena P Mota, Kiley M Yeaman, et al.JACC. Advances|June 28, 2024
Cardiopulmonary Exercise Testing in Pediatric Patients With Hypertrophic CardiomyopathyJonathan B Edelson, Helen M Stanley, Jungwon Min, et al.American Heart Journal|June 5, 2017
Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliationDavid J Goldberg, Victor Zak, Bryan H Goldstein, et al.Congenital Heart Disease|June 18, 2014
Survival data and predictors of functional outcome an average of 15 years after the Fontan procedure: the pediatric heart network Fontan cohortAndrew M Atz, Victor Zak, Lynn Mahony, et al.American Heart Journal|September 26, 2007
Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndromeRonald V Lacro, Harry C Dietz, Lisa M Wruck, et al.Pageof 9